ArticleScientific reports2026
Evaluation of salivary interleukin 6 interleukin 1 beta and interferon gamma in oral and mucocutaneous lichen planus patients.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lichen planus (LP) is an immune-mediated disorder affecting mucocutaneous tissues. This study aimed to evaluate and compare the salivary levels of interleukin (IL-6), interleukin-1 beta (IL-1β), and interferon-gamma (IFN-γ) in patients with oral lichen planus (OLP) and mucocutaneous lichen planus (MCLP) and to assess their correlation with disease severity. This prospective comparative study included 20 healthy controls (HCs) and 40 LP patients (20 OLP, 20 MCLP) matched for age and sex. All LP patients' diagnoses were clinically and histopathologically confirmed. Unstimulated saliva samples were collected. ELISA was used to measure cytokine levels. The clinical severity of OLP patients was assessed using the REU (reticulation/Erythema/ulceration) score. The level of IL-6 in patients with both OLP and MCLP was significantly greater than that in HCs (p < 0.001). The concentration of IL-1β was also greater in both groups than in the HC group, with no significant difference between the disease groups (p = 0.779). The IFN-γ levels in both groups were significantly greater than those in the HCs, with the levels in the MCLP group being significantly greater than those in the OLP group. IL-6 correlated with clinical severity in patients with OLP (ρ = 0.469; p = 0.037), while IL-1β correlated negatively with MCLP (ρ = -0.490; p = 0.028). This study is original in that it compared salivary cytokine profiles (IL-6, IL-1β, and IFN-γ) between OLPs and MCLPs. MCLP is associated with higher IFN-γ levels, and OLP is associated with higher IL-6 levels, indicating that these cytokines are promising biomarkers of disease severity. These findings support cytokine profiling as a noninvasive diagnostic tool and pave the way for personalized treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.